Cory Freedland Ph.D

Cory Freedland Ph.D General Information

Biography

Dr. Cory Freedland serves as a Partner at Samsara BioCapital. He serves as Board Member at Nalo Therapeutics, Nura Bio, Rainier Therapeutics, Omniox, OrsoBio, Palvella Therapeutics, and Tentarix Biotherapeutics. He also serves as Chief Investment Officer & Director at Jiya Acquisition. He also serves on the Board of Directors at Covid Apollo. He also served as an Associate at Sofinnova Ventures. He has been involved in the firm's investments in NuCana Biomed, Principia Biopharma, Spark Therapeutics, and ZS Pharma (ZSPH). Prior to Sofinnova, he was a Principal at Novo A/S. Before transitioning to life sciences finance, he worked as a research scientist for Roche focusing on preclinical drug discovery and novel target identification for psychiatric and neurodegenerative diseases. He moved to investment banking after Kellogg. Before his transition to healthcare venture, he was a Vice President in the healthcare investment banking practice at Morgan Stanley where he advised on over $12 billion of strategic and financing transactions in the biopharmaceutical and life science tools/diagnostics sectors. He also served as Board Member at Velicept Therapeutics. He received his Ph.D. in Pharmacology from Wake Forest University School of Medicine. He has an MBA from the Kellogg School of Management and holds a BA in Psychology and Religious Studies from Connecticut College.